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Abstract: Dietary modifications including plant stanol ester consumption are recommended measures
to control serum and low-density lipoprotein (LDL)-cholesterol concentrations, but obesity can affect
their responses. We investigated whether body mass index (BMI) affects serum cholesterol levels
during plant stanol (mainly sitostanol) ester consumption. This ad hoc analysis was based on
earlier results of a cross-over, randomized controlled trial of postmenopausal women consuming
rapeseed oil-based margarine without or with plant stanol ester (3 g plant stanols/day) for seven
weeks. We classified the subjects as normal-weight (BMI ≤ 25 kg/m2, n = 9, mean 22.6 kg/m2) or
overweight/obese (BMI > 25 kg/m2, n = 11, mean 28.4 kg/m2), and recalculated the results, focusing
on cholesterol absorption, cholesterol synthesis, and fecal steroid outputs. Serum cholesterol levels
were similar in the groups during the control diet. Plant stanol ester reduced serum cholesterol by
0.63 ± 0.19 mmol/L (11%) in normal-weight and by 0.75 ± 0.13 mmol/L (12%) in overweight/obese
subjects (p < 0.05 for both), and cholesterol absorption was reduced in both groups. However, relative
and dietary cholesterol absorption were more effectively reduced in normal-weight subjects. In
conclusion, overweight/obesity did not interfere with the serum cholesterol response to plant stanol
ester consumption despite substantial differences in cholesterol metabolism between the groups.
Keywords: atherosclerosis; cholesterol; cholesterol absorption; cholesterol synthesis; coronary artery
disease; LDL-cholesterol; obesity; overweight; plant stanol ester; sitostanol
1. Introduction
Cardiovascular diseases (CVDs) cause more disability-adjusted life-years (DALYs)
and deaths than any other disease group globally [1,2]. In 2017, CVDs caused almost
18 million deaths, of which about 12 million were caused by atherosclerotic cardiovascular
diseases (ASCVDs), i.e., coronary-artery disease (CAD), ischemic stroke, and peripheral-
artery disease [1]. Thus, ASCVD is still an important risk factor as regards human health.
The etiology of ASCVD is different from that of the other CVDs, because low-density
lipoproteins (LDLs) cause ASCVD [3,4].
Recent studies also highlighted the surprising frequency of subclinical atherosclerosis
in apparently healthy middle-aged subjects with a low risk of ASCVD [5–10]. Subclinical
atherosclerosis can proceed without symptoms to clinically evident ASCVD in a few years
in connection with circulating concentrations of low-density lipoprotein cholesterol (LDL-
C) [5–10]. However, its progression, as well as the risk of ASCVD events, can be prevented
by lowering LDL-C concentrations [9,11–14].
Dietary modifications including plant stanol ester consumption are recommended
measures to control LDL-C at a population level, and in hypercholesterolemic subjects
at risk of ASCVD, the latter in combination with drug treatment [15]. Plant stanols,
when consumed at a rate of two to three grams a day as fatty-acid esters, diminish the
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absorption of cholesterol by about 41–44% [16] and lower LDL-C concentrations on average
by 0.33–0.42 mmol/L (9–12%) [17]. The cholesterol-lowering mechanism of plant stanols
and plant sterols differs from those of other cholesterol-lowering dietary components by
providing additive cholesterol lowering when combined with other dietary components.
For example, plant stanol esters used as part of a heart-healthy diet can lower LDL-C
concentrations on average by 1.45 mmol/L (35%) compared with the habitual diet [18].
Plant stanols reduce the absorption of both cholesterol and plant sterols and can thus
preferentially be used in subjects with the gene variants in ABCG5/G8 transporters that
induce both elevated cholesterol and plant sterol absorption, leading to doubling of the
risk of CAD [19]. The overall incidence of these gene variants is relatively high, about 30%
at a population level, so the dietary use of plant stanols provides a safe way of mitigating
the implied risk.
Obesity can affect the serum cholesterol and LDL-C responses in dietary interven-
tions [20]. Thus, the substitution of unsaturated for saturated fatty acid intake reduced
serum cholesterol, LDL-C, and apoprotein B (apo B) concentrations more effectively in
normal-weight than in obese subjects [21]. The question arises of whether or not plant
stanol esters lower serum cholesterol concentrations less in obese than in normal-weight
subjects, since obesity markedly modifies cholesterol and LDL-apo B metabolism [22–26].
This study is an ad hoc analysis of an original randomized, controlled cross-over trial,
in which the effects of plant stanol ester consumption were evaluated in connection with
serum lipids, lipoproteins, and cholesterol and lipoprotein metabolism in postmenopausal
women with CAD [16]. For the present study, the original study population was classified
into normal-weight and overweight/obese subjects, and the results concerning serum
cholesterol and variables of cholesterol metabolism during control and intervention periods
were calculated in connection with the two groups. The primary outcome measures
were the obesity-related differences in serum cholesterol and in variables of cholesterol
metabolism at the end of control and plant stanol ester diet periods. The secondary outcome
measures were the relative changes brought about by use of plant stanol ester consumption
as compared to those of the placebo period in the respective variables in both groups.
2. Materials and Methods
2.1. Study Population
The original study involved 22 successive postmenopausal women with angiograph-
ically verified CAD treated at Helsinki University Central Hospital in 1994 [16]. The
subjects were studied in a steady state at least three months after myocardial infarction
or a coronary-artery procedure. The subjects had no liver, thyroid, or renal problems, or
diabetes mellitus, and no lipid-lowering treatment or estrogen-replacement therapy. In
1994, drug-based lipid-lowering therapy was not a routine regimen for CAD patients in
Finland. The mean age of the subjects was 51 years (range 48–56 years), their mean weight
68 kg (range 53–86 kg), and mean body mass index (BMI) 26 kg/m2 (range 21–33 kg/m2.
The present study population consisted of 20 subjects, because the original data
for two subjects were not available for recalculation. The subjects were classified into
normal-weight (BMI ≤ 25 kg/m2) and overweight/obese (BMI > 25 kg/m2) groups.
2.2. Study Procedure
A detailed description of this randomized, placebo-controlled, double blind cross-over
trial is available in Ref. [16]. A condensed scheme of the present study comparing the
end results between the active and control periods in the two BMI groups is presented in
Figure 1.




Figure 1. The study procedure. Each period lasted for 7 weeks. 
In brief, after a run-in period on their regular home diets, the subjects replaced in a 
randomized order 21 g of their daily total fat intake with a rapeseed oil-based margarine 
without (control diet) or with plant stanol ester (3 g plant stanols/day)(plant stanol ester 
diet) for seven weeks, followed by switching of the margarines for another 7-week period 
without a wash-out period. Since an earlier plant stanol ester intervention has demon-
strated that a steady state is achieved within 1–2 weeks without any carry-over effect [27], 
a wash-out period was considered unnecessary in this 7 + 7- week intervention. The plant 
stanols were mainly comprised of sitostanol, the most frequent plant stanols in food. The 
subjects were advised to use margarine daily in three divided doses during each of the 
three major meals.  
Blood samples were drawn after a 12-h fast at the end of the 7-week diet periods 
(Figure 1). At the same time the metabolic studies were performed with a focus on choles-
terol absorption [28], whole-body cholesterol synthesis, and fecal-steroid outputs. For this 
purpose, the subjects were given capsules to take three times a day for the last seven days 
of the periods, each capsule containing 14C-cholesterol, 3H-sitosterol, and Cr2O3. During 
these periods, each subject also kept a 7-day food diary. Three-day fecal collections were 
carried out at the end of the 7-day treatment periods.  
All subjects gave written informed consent. The study was performed according to 
the principles of the Declaration of Helsinki. The Ethics Committee of the Second Depart-
ment of Medicine, University of Helsinki approved the study protocol both to the basic 
and follow-up study.  
2.3. Methods 
Quantitation of serum concentrations of cholesterol, lathosterol, and sitosterol was 
performed using gas–liquid chromatography (GLC) with a 50-m capillary column (Ultra 
2, Agilent Technologies, Wilmington, DE, USA) and flame ionization detection with 5α-
cholestane as internal standard [29]. The samples from different times per subject were 
analyzed in the same GLC run. Serum concentrations of lathosterol and sitosterol were 
adjusted to those of cholesterol in the same GLC run and expressed as ratios to cholesterol 
(102 μmol/mmol cholesterol) to enable comparison between subjects with different LDL 
levels. Serum lathosterol and sitosterol ratios to cholesterol are validated biomarkers of 
cholesterol synthesis and cholesterol absorption efficiency [30–33]. Cholesterol synthesis 
was analyzed by using the sterol-balance technique. Fecal neutral sterols, bile acids, and 
plant stanols were analyzed by GLC [34]. Fecal neutral sterols denote excretion of choles-
terol and cholesterol-derived compounds to the feces, and fecal bile acids depict their de 
novo synthesis. Dietary intakes of cholesterol and fatty acids were analyzed by way of a 
computerized method, using data from the 7-day food diaries [35]. 
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In brief, after a run-in period on their regular home diets, the subjects replaced in a
randomized order 21 g of their daily total fat intake with a rapeseed oil-based margarine
without (control diet) or with plant stanol ester (3 g plant stanols/day)(plant stanol ester
diet) for seven weeks, followed by switching of the margarines for another 7-week period
without a wash-out period. Since an earlier plant stanol ester intervention has demonstrated
that a steady state is achieved within 1–2 weeks without any carry-over effect [27], a wash-
out period was considered unnecessary in this 7 + 7- week intervention. The plant stanols
were mainly comprised of sitostanol, the most frequent plant stanols in food. The subjects
were advised to use margarine daily in three divided doses during each of the three
major meals.
Blood samples were drawn after a 12-h fast at the end of the 7-week diet periods
(Figure 1). At the same time the metabolic studies were performed with a focus on
cholesterol absorption [28], whole-body cholesterol synthesis, and fecal-steroid outputs.
For this purpose, the subjects were given capsules to take three times a day for the last
seven days of the periods, each capsule containing 14C-cholesterol, 3H-sitosterol, and
Cr2O3. During these periods, each subject also kept a 7-day food diary. Three-day fecal
collections were carried out at the end of the 7-day treatment periods.
All subjects gave written informed consent. The study was performed according to the
principles of the Declaration of Helsinki. The Ethics Committee of the Second Department
of Medicine, University of Helsinki approved the study protocol both to the basic and
follow-up study.
2.3. Methods
Quantitation of serum concentrations of cholesterol, lathosterol, and sitosterol was
performed using gas–liq id hromatography (GLC) with a 50-m capill ry column (Ultra
2, Agilent Technologies, Wilmington, DE, USA) and flame ionization dete tion with 5α-
cholesta e as internal standard [29]. The samples from different times per subject were
analyzed in the same GLC run. Serum concentrations of lathosterol and sitosterol ere
djusted to those of cholesterol in the same GLC un and expressed as ratios to cholesterol
(102 µmol/mmol cholesterol) to enable compariso betw en subject with different LDL
levels. Serum lathosterol and sitosterol ratios to chol sterol are validated biomarkers of
chole terol synthesi and choles erol absorption effici ncy [30–33]. Chol ster l synthesis
was analyzed by using the st rol-balance technique. Fecal neutral sterols, bile acids,
and plant stanols were analyzed y GLC [34]. Fecal neutral s erols denote excretion of
cholesterol and cholesterol-derived compounds to the feces, and fecal bile acids depict
their de nov synthesis. Dietary intakes of cholesterol fatty acids were analyzed by
way of a computerized method, using data from the 7-day food diaries [35].
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2.4. Calculations
Cholesterol synthesis = (fecal elimination of cholesterol as neutral sterols plus bile
acids) − dietary cholesterol intake.
Total intestinal cholesterol pool = fecal neutral sterols/(100 − cholesterol absorption
efficiency).
Dietary intestinal cholesterol pool = dietary cholesterol intake.
Biliary intestinal cholesterol pool = total intestinal cholesterol pool − dietary choles-
terol intake.
Total cholesterol absorbed = cholesterol absorption efficiency × total intestinal choles-
terol pool/100.
Dietary cholesterol absorbed = cholesterol absorption efficiency × dietary cholesterol
intake.
Biliary cholesterol absorbed = Total cholesterol absorbed − Dietary cholesterol absorbed.
2.5. Statistics
Statistical analyses were performed by using SPSS for Windows 22.0 (SPSS, Chicago,
IL, USA). Sample-size calculation was based on significance levels (a = 0.05 and b = 0.20)
and essential information obtained from the previous study [16]. Using these estimates,
the size of the required population was 21, suggesting that the size of the present study
population was appropriate. Normality and homogeneity of variance assumptions were
checked before further analyses, and variables not normally distributed were transformed
logarithmically. Continuous variables were tested by using Student’s t-test. Variables
not normally distributed even after logarithmic transformation, or nonhomogeneous in
variance, were tested by using Mann–Whitney U-tests. A two-sided p-value of <0.05 was
considered statistically significant. The results are expressed as means ± SEs.
3. Results
3.1. Serum Sterols and Variables of Cholesterol Metabolism during the Control Diet
Of the twenty subjects, nine belonged to the normal-weight (BMI ≤ 25 kg/m2) and 11
to the overweight/obese (BMI > 25 kg/m2) group (Table 1). The age of the subjects did
not differ between the groups. The dietary intakes of cholesterol and total fatty acids were
similar in the two groups. Fecal plant stanol concentrations, robustly depicting their dietary
intake because of their low absorption of <0.2% [36], were also similar in the two groups.
Table 1. Characteristics of the study population divided into normal-weight (BMI ≤ 25 kg/m2) and overweight/obese
(BMI > 25 kg/m2) subjects during the control and plant stanol ester diets.
Variables Normal-Weight Subjects, n = 9 Overweight/Obese Subjects, n = 11
Control Diet Plant-Stanol-ester Diet Control Diet Plant-Stanol-ester Diet
Age, years 53 ± 0.7 52 ± 0.8
Weight, kg 58 ± 1 58 ± 1 74 ± 2 * 74 ± 2 *
BMI, kg/m2 22.6 ± 0.4 22.4 ± 0.5 28.4 ± 0.7 * 28.4 ± 0.7 *
Dietary cholesterol, mg/day 231 ± 26 220 ± 34 185 ± 20 200 ± 24
Dietary total fatty acids, g/day 73 ± 54 70 ± 6 60 ± 4 57 ± 4
Fecal plant stanols, mg/day 28 ± 13 2629 ± 296 † 39 ± 21 2596 ± 239 †
Mean ± SE. BMI = body mass index. * p < 0.05 vs. normal-weight subjects, † p < 0.05 vs. the control diet.
Serum cholesterol concentrations were mildly to moderately elevated and similar in
the groups (Table 2). Serum triglyceride levels were within the normal range in both groups
(0.9 ± 0.2 mmol/L, BMI ≤ 25 kg/m2 and 1.5 ± 0.3 mmol/L, BMI > 25 kg/m2). Measures
of cholesterol absorption efficiency, serum sitosterol, and dietary cholesterol absorbed were
lower in the overweight/obese subjects compared with the normal-weight subjects. The
amounts of biliary and total cholesterol absorbed were not affected by BMI.
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Table 2. Serum sterol concentrations and variables of cholesterol metabolism in the study population
divided into normal-weight (BMI ≤ 25 kg/m2) and overweight/obese (BMI > 25 kg/m2) subjects at
the end of the control and plant stanol ester diets.
Variables Control Diet Plant-Stanol-Ester Diet
Serum cholesterol, mmol/L
BMI ≤ 25 kg/m2, n = 9 5.82 ± 0.30 5.19 ± 0.38 *
BMI > 25 kg/m2, n = 11 6.00 ± 0.28 5.24 ± 0.22 *
p-value 1 0.849 0.518
Serum lathosterol 2
BMI ≤ 25 kg/m2, n = 9 139 ± 14 165 ± 19
BMI > 25 kg/m2, n = 11 189 ± 14 206 ± 20
p-value 1 0.037 0.138
Serum sitosterol 2
BMI ≤ 25 kg/m2, n = 9 185 ± 19 137 ± 16 *
BMI > 25 kg/m2, n = 11 116 ± 12 89 ± 9 *
p-value 1 0.017 0.030
Cholesterol absorption efficiency, %
BMI ≤ 25 kg/m2, n = 9 49 ± 3 24 ± 3 *
BMI > 25 kg/m2, n = 11 37 ± 2 22 ± 1 *
p-value 1 0.007 0.543
Total cholesterol absorbed 3
BMI ≤ 25 kg/m2, n = 9 479 ± 46 246 ± 35 *
BMI > 25 kg/m2, n = 11 483 ± 53 295 ± 15 *
p-value 1 0.569 0.382
Dietary cholesterol absorbed 3
BMI ≤ 25 kg/m2, n = 9 113 ± 13 58 ± 14 *
BMI > 25 kg/m2, n = 11 67 ± 7 43 ± 5 *
p-value 1 0.007 0.790
Biliary cholesterol absorbed 3
BMI ≤ 25 kg/m2, n = 9 365 ± 39 188 ± 24 *
BMI > 25 kg/m2, n = 11 416 ± 52 252 ± 15 *
p-value 1 0.425 0.074
Total intestinal cholesterol pool 3
BMI ≤ 25 kg/m2, n = 9 966 ± 65 986 ± 60
BMI > 25 kg/m2, n = 11 1322 ± 143 1333 ± 62
p-value 1 0.044 0.003
Dietary intestinal cholesterol pool 3
BMI ≤ 25 kg/m2, n = 9 230 ± 26 220 ± 34
BMI > 25 kg/m2, n = 11 185 ± 20 200 ± 24
p-value 1 0.184 0.732
Biliary intestinal cholesterol pool 3
BMI ≤ 25 kg/m2, n = 9 735 ± 51 766 ± 48
BMI > 25 kg/m2, n = 11 1137 ± 141 1133 ± 59
p-value 1 0.004 0.001
Fecal bile acids 3
BMI ≤ 25 kg/m2, n = 9 316 ± 37 324 ± 36
BMI > 25 kg/m2, n = 11 349 ± 30 305 ± 28
p-value 1 0.425 0.518
Fecal neutral sterols 3
BMI ≤ 25 kg/m2, n = 9 487 ± 40 740 ± 44 *
BMI > 25 kg/m2, n = 11 839 ± 99 1038 ± 56
p-value 1 0.002 0.002
Cholesterol synthesis 3
BMI ≤ 25 kg/m2, n = 9 572 ± 54 844 ± 63 *
BMI > 25 kg/m2, n = 11 1003 ± 111 1143 ± 58
p-value 1 0.001 0.006
Mean ± SE. BMI = body mass index. Fecal neutral sterols = excretion of cholesterol and cholesterol-derived
compounds to feces. 1 Mann–Whitney U-test between the BMI groups, 2 102 µmol/mmol cholesterol, 3 mg/day.
* p < 0.05 vs. the control diet, paired t-test.
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Measures of cholesterol synthesis, serum lathosterol, fecal neutral sterols denoting
the excretion of cholesterol and cholesterol-derived compounds to the feces, and biliary
and total intestinal cholesterol pools were higher in the overweight/obese subjects than
in the normal-weight subjects (Table 2). The dietary cholesterol pool and fecal bile-acid
concentrations were identical in the two groups.
3.2. Plant Stanol Ester Consumption, Serum Sterols, and Variables of Cholesterol Metabolism
Plant stanol ester margarine was well tolerated and no side effects were reported.
Dietary intakes of cholesterol and total fatty acids were similar in the normal-weight
and overweight/obese subjects, as they were in the control period (Table 1). Fecal plant
stanol concentrations increased from the control diet values to about 2600 mg/day during
the plant stanol ester diet (Table 1). The amounts of fecal plant stanols ranged between
1729–3529 mg/day in the normal-weight subjects and 1836–3421 mg/day in the over-
weight/obese subjects.
Serum cholesterol levels were reduced similarly in both groups, by 0.63 ± 0.19 mmol/L
(11%) in the normal-weight subjects and by 0.75 ± 0.13 mmol/L (12%) in the over-
weight/obese subjects (p < 0.05 for both) (Table 2, Figure 2). Serum triglyceride con-
centrations were unchanged from the control-diet values and similar in the two groups
(1.0 ± 0.2 mmol/L, BMI ≤ 25 kg/m2 and 1.4 ± 0.2 mmol/L, BMI > 25 kg/m2).




Figure 2. Relative changes (mean ± SE) caused by the plant stanol ester diet compared with the 
control diet in serum cholesterol concentrations and variables of cholesterol absorption in the 
study population divided into normal-weight (BMI ≤ 25 kg/m2) and overweight/obese (BMI > 25 
kg/m2) subjects. * p < 0.05 between the plant stanol ester vs. the control diet, └*┘ p < 0.05 between 
the BMI groups. 
4. Discussion 
This randomized, cross-over. and placebo-controlled intervention shows that an 
overweight/obese condition did not affect serum cholesterol lowering by means of plant 
stanol ester consumption. In addition, obesity-induced elevated cholesterol synthesis did 
not increase serum cholesterol concentrations.  
Our novel findings demonstrated that consuming plant stanol esters by an intake of 
2.6 g of plant stanols/day (Table 1; fecal plant stanols) significantly lowered serum choles-
terol concentrations by 0.63 and 0.75 mmol/L (11% and 12%) in the normal-weight and 
overweight/obese subjects in spite of substantial differences in cholesterol metabolism be-
tween the groups. Relative and absolute cholesterol absorption diminished in both groups 
during the plant stanol ester diet compared with the control period. However, the relative 
cholesterol absorption efficiency and dietary cholesterol absorbed were more effectively 
reduced in the normal-weight than in the overweight/obese subjects. Cholesterol synthe-
sis and excretion of cholesterol and cholesterol-derived compounds to the feces, denoted 
as fecal neutral sterols, increased significantly only in the normal-weight subjects. Never-
theless, cholesterol synthesis, fecal neutral sterols, and the total and biliary intestinal cho-
lesterol pools remained larger during the plant stanol ester diet in the overweight/obese 
subjects than in the normal-weight subjects.  
During the control diet, cholesterol metabolism differed in the normal-weight and 
overweight/obese subjects more or less as described in earlier studies [22–26,37]. The only 
differences in the present vs. earlier studies were the lower amount of dietary cholesterol 
absorbed in the overweight/obese than in the normal-weight subjects and the similar lev-
els of fecal bile acids in the two groups. Instead, plant stanol-induced effects on serum 
cholesterol concentration and on variables of cholesterol metabolism in normal-weight 
subjects were similar as described earlier [16,38–41]. Thus, it can be concluded that this 
study population was adequate and also large enough for statistical analyses, in conform-
ity with the power calculation and earlier studies. However, if the research methodology 
i re . l i c a ges ( ean ± SE) caused by the plan stanol ster diet compared with the
control diet in seru cholesterol concentrations and variables of cholesterol absorption in the study
population divided into normal-weight (BMI ≤ 25 kg/m2) and overweight/obese (BMI > 25 kg/m2)
subjects. * p < 0.05 between the plant stanol ester vs. the control diet,C*A p < 0.05 between the
BMI groups.
Measures of cholesterol absorption efficiency, serum sitosterol, and dietary, biliary,
and total cholesterol absorbed decreased after intake of dietary plant stan ls in both groups
(Table 2). However, relative cholesterol absorption fficiency and dietary cholesterol
absorb d de reased m re i the n rmal-weight than in the overweight/obese subjects
(Table 2, Figur 2).
Measures o cholesterol sy thesis and fecal neutral sterols increas d only in the ormal-
wei ht subjects, although they remained at lower levels than in the ov rw ight/obese
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subjects (Table 2). Serum lathosterol concentrations showed only a tendency to reflect
changes in cholesterol synthesis. Intestinal cholesterol pools remained practically un-
changed in both groups. Hence the biliary and total intestinal cholesterol pools remained
larger in the overweight/obese subjects than in the normal-weight subjects. Fecal bile acid
levels were unchanged in both groups.
4. Discussion
This randomized, cross-over. and placebo-controlled intervention shows that an
overweight/obese condition did not affect serum cholesterol lowering by means of plant
stanol ester consumption. In addition, obesity-induced elevated cholesterol synthesis did
not increase serum cholesterol concentrations.
Our novel findings demonstrated that consuming plant stanol esters by an intake
of 2.6 g of plant stanols/day (Table 1; fecal plant stanols) significantly lowered serum
cholesterol concentrations by 0.63 and 0.75 mmol/L (11% and 12%) in the normal-weight
and overweight/obese subjects in spite of substantial differences in cholesterol metabolism
between the groups. Relative and absolute cholesterol absorption diminished in both
groups during the plant stanol ester diet compared with the control period. However, the
relative cholesterol absorption efficiency and dietary cholesterol absorbed were more effec-
tively reduced in the normal-weight than in the overweight/obese subjects. Cholesterol
synthesis and excretion of cholesterol and cholesterol-derived compounds to the feces,
denoted as fecal neutral sterols, increased significantly only in the normal-weight subjects.
Nevertheless, cholesterol synthesis, fecal neutral sterols, and the total and biliary intestinal
cholesterol pools remained larger during the plant stanol ester diet in the overweight/obese
subjects than in the normal-weight subjects.
During the control diet, cholesterol metabolism differed in the normal-weight and
overweight/obese subjects more or less as described in earlier studies [22–26,37]. The only
differences in the present vs. earlier studies were the lower amount of dietary cholesterol
absorbed in the overweight/obese than in the normal-weight subjects and the similar
levels of fecal bile acids in the two groups. Instead, plant stanol-induced effects on serum
cholesterol concentration and on variables of cholesterol metabolism in normal-weight
subjects were similar as described earlier [16,38–41]. Thus, it can be concluded that this
study population was adequate and also large enough for statistical analyses, in conformity
with the power calculation and earlier studies. However, if the research methodology
would be less demanding for both the participants and for the laboratory, a larger number
of especially obese subjects would have been optimal.
Why is it then that plant stanol esters lowered serum cholesterol concentrations
similarly in the two groups in spite of differences in cholesterol metabolism, and why is
it that the elevated level of cholesterol synthesis in obese subjects did not result in higher
blood cholesterol values? According to what we know of cholesterol homeostasis, low
cholesterol absorption upregulates hepatic cholesterol synthesis. Upregulated cholesterol
synthesis is in general associated with upregulated expression of LDL receptors. In fact,
upregulated expression of LDL receptors leading to increased catabolism of LDL-apo B has
been demonstrated in obese vs. normal-weight subjects [42]. In combination with changes
in very-low-density lipoprotein (VLDL)-apo B metabolism, typical of obesity, increased
LDL-apo B catabolism together with decreased LDL-apo B production in obesity result in
similar serum cholesterol concentrations in obese and normal-weight subjects [42]. Since
also plant stanol ester consumption increases LDL-apo B catabolism [43], these findings
appeared to explain the similar serum cholesterol concentrations in the two groups in this
study during both dietary periods.
An interesting finding regarding cholesterol absorption was the surprisingly simi-
lar amounts of total absolute cholesterol absorbed daily in the normal-weight and over-
weight/obese subjects during both diet periods. Plant stanol ester consumption resulted in
a higher daily level of absolute absorption of cholesterol (mean of 49 mg more) in the over-
weight/obese subjects compared with the normal-weight subjects and this was reflected in
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reduced fecal excretion of cholesterol and its metabolites in the overweight/obese subjects
(54 mg/day less).
Effective reduction of dietary cholesterol in particular may be of importance from a
cardioprotective point of view. It was recently shown that each additional intake of 300 mg
of dietary cholesterol/day predicted a 17% higher risk of incident CVD and an 18% higher
risk of all-cause mortality [44]. Further, in the same study, consuming half an egg/day,
corresponding to 93 mg of cholesterol, on average, predicted a 6% higher risk of incident
CVD and an 8% higher risk of all-cause mortality. Thus, it is possible that the amount of
dietary cholesterol has a role in atherosclerosis, the mechanism of which remains to be
evaluated further.
Even though the cholesterol-lowering efficacy of plant stanol esters was comparable in
the two groups with a similar plant stanol dose, the large intestinal cholesterol pool in obese
or morbidly obese subjects may dilute the concentration of plant stanols in the intestine and
diminish their cholesterol-lowering efficacy. In fact, in this study only a limited number of
subjects were obese (BMI 30–34 kg/m2) and no one was morbidly obese (BMI ≥ 35 kg/m2).
A larger dose of plant stanols may be needed in obese and morbidly obese subjects.
Daily intake of plant stanols dose-dependently reduces serum concentrations of plant
sterols, these representing a reliable biomarker of cholesterol absorption during plant
stanol ester use [45]. Thus, since 2.0 g/day of plant stanols as esters lower LDL-C levels
by 0.33 mmol/L in normal-weight subjects [17], in obesity the respective dose should be
increased to 3.0 g/day to keep the intestinal plant stanol to cholesterol ratio equal to that
in normal-weight subjects. This calculation was based on total intestinal pool sizes in
normal-weight and obese subjects during a habitual home diet [22].
Our study had the following limitations. The number of subjects was limited although
it can be considered of adequate size as regards the power calculation, and the similarity
of the results to those of earlier studies dealing with cholesterol metabolism in obesity in
general and plant stanol ester consumption-derived metabolic changes. However, whether
or not plant stanol ester consumption also lowers serum levels of total and LDL-C in obese
and morbidly obese subjects and without modifying the plant stanol dose remains to be
evaluated further. It should be acknowledged that conducting a large clinical study with
the same measurements of cholesterol metabolism, including the sterol balance technique,
would be challenging to execute today.
In conclusion, we demonstrated here that plant stanol ester consumption effectively
lowers serum cholesterol concentrations in overweight/obese postmenopausal women
with CAD compared with normal-weight controls. Consumption of plant stanols as fatty
acid esters as part of a heart-healthy diet is a recommended means of controlling LDL-C
concentrations in order to prevent the development of subclinical atherosclerosis and
ASCVD at a population level, and in subjects at risk of ASCVD in combination with drug
treatment. Especially combined with statin treatment, a plant stanol or plant sterol-enriched
diet significantly lowers serum cholesterol and LDL-C concentrations by 0.30 mmol/L
compared with statins alone [46]. However, more information is needed in connection
with morbid obesity, especially as regards adequate doses of plant stanols in these subjects.
Finally, regarding the recent information that an increase in dietary cholesterol intake is
associated with the risk of ASCVD events, a reduction of dietary cholesterol absorption
through the use of plant stanol esters might turn out to be a valuable health benefit added to
its LDL-C-lowering effect. Thus, the use of plant stanol esters is recommended in subjects
with gene variants that increase cholesterol absorption, leading to an increased risk of CAD.
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